The Medicines and Healthcare products Regulatory Agency has suspended the licence for lumiracoxib (Prexige®) according to a press release.
Earlier this year restrictions were introduced following safety concerns about possible liver damage. A review of the most recent worldwide data has shown that liver reactions have occurred in patients taking low doses and for short periods.
Patients who are taking lumiracoxib and who feel well may continue with treatment but are advised to book a non urgent appointment to discuss alternative treatments. Patients taking the drug who feel unwell (particularly nausea, vomiting, loss of appetite, tiredness, stomach pains, dark urine, or itching or yellowing of the skin [jaundice]) are advised to stop treatment immediately.
Action: Clinicians should be aware of this licence suspension. Patients will need their treatment reviewed and a suitable alternative should be prescribed.
|« Vildagliptin delayed||Strontium ranelate safety warning »|